EP0188590A1 - Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same - Google Patents

Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same

Info

Publication number
EP0188590A1
EP0188590A1 EP85903869A EP85903869A EP0188590A1 EP 0188590 A1 EP0188590 A1 EP 0188590A1 EP 85903869 A EP85903869 A EP 85903869A EP 85903869 A EP85903869 A EP 85903869A EP 0188590 A1 EP0188590 A1 EP 0188590A1
Authority
EP
European Patent Office
Prior art keywords
diseases
virus
preparations
treatment
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP85903869A
Other languages
German (de)
French (fr)
Inventor
Laszlo Csatary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP0188590A1 publication Critical patent/EP0188590A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Definitions

  • the present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used.
  • the Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
  • Attenuated viral vaccines pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
  • the ob ject of the present invention is a set of preparations containing attenuated (or killed)
  • Newcastle disease virus Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans.
  • the present invention relates also to all materials and methods used in the production of all preparations. The Preparations have already been used with very good result in the conditions listed below:
  • the Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious monon ⁇ cleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
  • the Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
  • the Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology.
  • the Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
  • the optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial.
  • the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
  • the dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated.
  • the Preparations are non-toxic , and have no side effect whatever.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Préparations thérapeutiques contre certaines maladies d'origine virale ou autre chez l'homme. Ces préparations sont spécifiées en tant que formules contenant le virus atténué de la maladie de Newcastle, le virus de la maladie de Marek, le virus de la bronchite chez les aviens ou le virus de l'encéphalite chez les aviens, mélangés dans une substance-véhicule utilisée généralement en pharmacologie humaine, éventuellement avec une ou plusieurs préparations de renforcement. Un autre objet de l'invention est l'utilisation de ces virus dans le traitement de maladies d'origine virale, ainsi que de tumeurs bénignes et malignes et de maladies du collagène.Therapeutic preparations against certain diseases of viral or other origin in humans. These preparations are specified as formulas containing the attenuated Newcastle disease virus, the Marek's disease virus, the bronchitis virus in avians or the encephalitis virus in avians, mixed in a substance- vehicle generally used in human pharmacology, possibly with one or more reinforcing preparations. Another object of the invention is the use of these viruses in the treatment of diseases of viral origin, as well as benign and malignant tumors and diseases of collagen.

Description

THE REPAUTIC PREPARATIONS FOR TREATMENT OF CERTAIN VIRAL AND OTTER DISEASES AND THE PREPARATION OF THE SAME
Technical field
The present invention relates to a set of therapeutic preparations (further on Preparation (s ) ) for the treatment of certain viral and other diseases , together with the complete technics of their production , including all materials and methods used. The Preparations are effective against various pathological conditions caused by the Herpes group of viruses , and against certain malignant and benign tumours and collagen diseases as well.
Background art
Inactivated or live attenuated viruses have long been used all over the world for the specific prevention of several viral diseases of humans and animals. We have found that certain attenuated viral vaccines , pre pared against some viral diseases of animals (Newcastle disease , Marek 's disease , avian bronchitis , avian encephalitis ) had a distinct therapeutic effect against various human diseases of known viral or unknown etiology.
Disclosure of invention
Accordingly the ob ject of the present invention is a set of preparations containing attenuated (or killed)
Newcastle disease virus , Marek's disease virus , avian bronchitis virus or avian encephalitis virus , mixed in a carrier which is acceptable for use in humans. The present invention relates also to all materials and methods used in the production of all preparations. The Preparations have already been used with very good result in the conditions listed below:
1. The Preparation containing attenuated Newcastle disease virus was active against the followin g conditions : a) Infections caused by viruses of the Herpes group , such as Herpex simplex I and II , Herpes zooster, Cytomegalovirus , infectious mononυcleoses (EpsteinBarr virus ) b) Aphthostomatitis c) Verruca vulgaris d) Infantile pharyngeal papilloma e) Human aden oca rein omas f ) Collagen diseases (e. g. nodous polyarteritis) g) Rheumatic arthritis
2. The Preparation containing attenuated Marek's disease virus acted against the following conditions : a ) Various human cancers (mainly a den oca rein omas ) b) Infections caused by viruses of the Herpes group as listed above (1.a)
3. The Prepa ration containing attenuated avian bronchitis virus was active against the following conditions : a) Various human cancers b) Infections caused by the above listed (1.a) viruses of the Herpes goup.
4. The Preparation containing attenuated avian encephalitis virus was active against the following conditions : a) Various human cancers
While most vaccines used for specific disease prevention in humans contain killed (inactivated) virus , all Preparations contain live attenuated virus. The possible mechanism of action of the Preparations is thus either an interference with the virulent viruses responsible for the actual disease , or a highly efficient aspecific stimulation of the natural protective mechanisms operative in the organism involved by disease.
The Preparations are produced by suspending live attenuated or inactivated , purified or highly purified and concentrated viruses in one of the carrier substances generally used in human pharmacology. The Preparations may be supplemented with potentiating drugs (e.g. tranquilizers).
The optimal form of delivery of the Preparations is in a freeze-dried form , in sealed ampoules , with the diluent supplied in a separate vial. In this form , the Preparations can be stored at room temperature for a practically unlimited time, toother forms of delivery are in solution , suppository , capsule , emulsion , suspension , ointment , etc. These should be stored in cold , for their activity may decay repidly at room temperature.
The dosage of the Preparations depends of their actual composition and form , on the patient 's general condition , and on stage (severity) of the disease actually treated. The Preparations are non-toxic , and have no side effect whatever.
The Preparations were tested in humans and animals , and showed a great therapeutic efficiency in both clinical and experimental trials.

Claims

Claims
1. Therapeutic preparation for the treatment of viral diseases and against malignant and benign tumours and collagen diseases characterized by containing live attenuated viruses selected from the group consisting of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus.
2. The preparation according to claim 1 characterized by containing at least one carrier.
3. Use of Newcastle disease virus , Marek's disease virus , avian bronchitis virus and avian encephalitis virus in the treatment of viral diseases , against malignant and benign tumours and collagen diseases.
4. The use of viruses according to claim 3 in the treatment of diseases caused by the Herpes group of viruses.
EP85903869A 1984-07-30 1985-07-29 Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same Withdrawn EP0188590A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU291984 1984-07-30
HU842919A HU197517B (en) 1984-07-30 1984-07-30 Process for production of terapeutical composition applicable against virus infection

Publications (1)

Publication Number Publication Date
EP0188590A1 true EP0188590A1 (en) 1986-07-30

Family

ID=10961677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP85903869A Withdrawn EP0188590A1 (en) 1984-07-30 1985-07-29 Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same

Country Status (4)

Country Link
EP (1) EP0188590A1 (en)
AU (1) AU4638085A (en)
HU (1) HU197517B (en)
WO (1) WO1986000811A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1292691C (en) * 1986-09-15 1991-12-03 Allen D. Allen Method for the effective treatment of disease conditions in humans associated with htl virus infection
NZ224567A (en) * 1987-05-19 1990-08-28 Yissum Res Dev Co Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
DE3816139A1 (en) * 1987-10-17 1989-04-27 Bayer Ag METHOD FOR PRODUCING PARAMUNITY INDUCERS
DE3806565A1 (en) * 1988-03-01 1989-09-14 Deutsches Krebsforsch VIRUS-MODIFIED TUMOR VACCINES FOR THE IMMUNOTHERAPY OF TUMOR METAL KEYS
AU673827B2 (en) * 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
DK1486211T3 (en) 1993-04-30 2009-01-19 Wellstat Biologics Corp Compositions for the treatment of cancer using viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
CN1477964A (en) 1999-04-15 2004-02-25 Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
ES2380289T3 (en) 2009-11-30 2012-05-10 United Cancer Research Institute New clone of Newcastle disease virus, its manufacture and application in the medical treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES284278A1 (en) * 1962-02-01 1963-06-16 Philips Roxane Incorporated A method for selecting a virus (Machine-translation by Google Translate, not legally binding)
GB1292803A (en) * 1968-11-18 1972-10-11 Nat Res Dev Improvements relating to the production of antigens
US3548054A (en) * 1969-06-06 1970-12-15 Lilly Co Eli Method for improving weight gains and reducing gross lesions in chickens exposed to marek's disease
DK124340B (en) * 1969-11-29 1972-10-09 Takeda Chemical Industries Ltd Method for producing strong attenuated, live Newcastle disease virus vaccine.
US3642574A (en) * 1970-04-29 1972-02-15 Us Agriculture Method for producing vaccine for immunization of poultry against marek{3 s disease
ZA743771B (en) * 1973-07-19 1975-07-30 M Sevoian Vaccine and preparation thereof
US4049794A (en) * 1974-06-24 1977-09-20 Bayer Aktiengesellschaft Treatment of infections in animals
ZA754725B (en) * 1974-08-01 1976-06-30 H Stickl Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
PT70556A (en) * 1978-12-20 1980-01-01 Gist Brocades Nv Vaccines against diseases caused by reo-virus and process for the preparation of those vaccines
US4357320A (en) * 1980-11-24 1982-11-02 Gist-Brocades N. V. Infectious bronchitis vaccine for poultry
JPS58116422A (en) * 1981-12-28 1983-07-11 Green Cross Corp:The Antitumor agent
GB2114438A (en) * 1982-02-05 1983-08-24 Akzo Nv Infectious bronchitis vaccines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8600811A1 *

Also Published As

Publication number Publication date
WO1986000811A1 (en) 1986-02-13
HU197517B (en) 1989-04-28
HUT40572A (en) 1987-01-28
AU4638085A (en) 1986-02-25

Similar Documents

Publication Publication Date Title
Potkay Diseases of the Callitrichidae: a review
Habel et al. Relationship of polyoma virus and tumor in vivo
Käufer et al. Significance of bursa of Fabricius as target organ in infectious bursal disease of chickens
US4053582A (en) Attenuated fowl pox virus preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
Hilleman Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man
EP0188590A1 (en) Therapeutic preparations for treatment of certain viral and other diseases and the preparation of the same
US5484589A (en) Anti-viral methods using RNAse and DNAse
Coggeshall et al. THE EFFECTIVENESS OF TWO NEW TYPES OF CHEMOTHERAPEUTIC AGENTS IN MALARIA: SODIUM P, P′-DIAMINODIPHENYLSULFONE N, N′-DIDEXTROSESULFONATE (PROMIN) AND 2-SULFANILAMIDO PYRIMIDINE (SULFADIAZINE)
EA200100302A1 (en) METHODS AND COMPOSITIONS FOR PROTECTIVE AND THERAPEUTIC GENETIC IMMUNIZATION
Cabasso et al. Propagation of Canine Distemper Virus on the Chorio-Allantolc Membrane of Embryonated Hen Eggs
JPH11514990A (en) Use of 2-mercaptoethanolamine (2-MEA) and related aminothiol compounds and copper 3,5-diisopropylsalicylate (II) and related compounds for preventing and treating various diseases
Forman et al. Studies with foot-and-mouth disease virus in British deer (red, fallow and roe): 1. Clinical disease
EP0188499A1 (en) An antiviral preparation and the method of its production
US4049794A (en) Treatment of infections in animals
US4039656A (en) Production of attenuated viruses
AU2009100451A4 (en) Medicinal formulation containing a combination of HIV Type I and HIV Type II
Melnick et al. Photodynamic inactivation of herpesvirus
JPS58103324A (en) Interferon composition and use for herpes infection treatment
Lockart Jr Variations in the abilities of several lines of L cells to produce and to be affected by interferon
KR970005329B1 (en) Composition for the treatment of mammalian retrovirus infection
US4017359A (en) Production of non-antigenic attenuated viruses
US6080726A (en) Anti-viral and immuno stimulator polynucleotide duplex and use thereof
JPH05262653A (en) Therapeutic composition of acquired immunodeficiency syndrome (aids)
WO2004004764A1 (en) Composition against white spot disease
RU1808324C (en) Method for prophylaxis and treatment of caseinobesoardic disease in neonatal calves

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19860703